Hologic

Hologic, Inc., headquartered in Marlborough, Massachusetts, is a highly innovative, purpose-driven global medical technology company primarily focused on dramatically improving women’s health and well-being through early disease detection and highly targeted treatment. The organization dominates several distinct, highly critical diagnostic and surgical markets, establishing itself as an irreplaceable partner in the healthcare ecosystem.

In the diagnostics sector, Hologic is best known for fundamentally revolutionizing cervical cancer screening globally with the widely adopted ThinPrep® Pap Test. They have further solidified their diagnostic leadership with their highly advanced Aptima® assays for sexually transmitted infections (STIs), which operate on their proprietary, fully automated Panther® system. The Panther system has become an absolute cornerstone of modern molecular diagnostics laboratories, offering unmatched workflow automation and a vast, continuously expanding menu for infectious disease testing—a scalable capability that proved critical during the global COVID-19 response.

Beyond molecular diagnostics, Hologic is the undisputed global market leader in breast cancer screening. The company pioneered and commercialized 3D mammography (tomosynthesis) technology—most notably through its Selenia® Dimensions® and 3Dimensions™ platforms—which significantly and definitively improves invasive cancer detection rates compared to traditional 2D mammograms.

Complementing its diagnostic and imaging portfolios, the company also develops and offers advanced, minimally invasive surgical products dedicated to gynecological health. Hologic’s deeply rooted, unapologetic focus on women’s healthcare, combined with relentless technological innovation in molecular diagnostics, medical imaging, and surgical intervention, solidifies its position as a foundational pillar of modern, specialized medical care.